Cargando…

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism

The impact of JAK/STAT inhibitors, which are used in various inflammatory diseases, on cardiovascular risk is controversial and has recently raised safety concerns. Our study investigates the direct effects of tofacitinib on macrophage cholesterol metabolism, which is crucial for atherosclerosis pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adorni, Maria Pia, Papotti, Bianca, Borghi, Maria Orietta, Raschi, Elena, Zimetti, Francesca, Bernini, Franco, Meroni, Pier Luigi, Ronda, Nicoletta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454555/ https://www.ncbi.nlm.nih.gov/pubmed/37628747 http://dx.doi.org/10.3390/ijms241612571

Ejemplares similares

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives
por: Adorni, Maria Pia, et al.
Publicado: (2021)

PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease
por: Papotti, Bianca, et al.
Publicado: (2022)

Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis
por: Karpouzas, George Athanasios, et al.
Publicado: (2022)

HDL Cholesterol Efflux and Serum Cholesterol Loading Capacity Alterations Associate to Macrophage Cholesterol Accumulation in FH Patients with Achilles Tendon Xanthoma
por: Adorni, Maria Pia, et al.
Publicado: (2022)

HDL metabolism and functions impacting on cell cholesterol homeostasis are specifically altered in patients with abdominal aortic aneurysm
por: Adorni, Maria Pia, et al.
Publicado: (2022)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
por: Adorni, Maria Pia, et al.
Publicado: (2019)

Statins influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis
por: Karpouzas, George A., et al.
Publicado: (2023)

Inflammation and immunomodulatory therapies influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis
por: Karpouzas, George A., et al.
Publicado: (2023)

Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study
por: Greco, Daniela, et al.
Publicado: (2020)

Effects of Antirheumatic Treatment on Cell Cholesterol Efflux and Loading Capacity of Serum Lipoproteins in Spondylarthropathies
por: Hokstad, Ingrid, et al.
Publicado: (2022)

HDL Proteome and Alzheimer’s Disease: Evidence of a Link
por: Marsillach, Judit, et al.
Publicado: (2020)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Hydroxypropyl-β-Cyclodextrin Depletes Membrane Cholesterol and Inhibits SARS-CoV-2 Entry into HEK293T-ACE(hi) Cells
por: Alboni, Silvia, et al.
Publicado: (2023)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
por: Di Benedetto, Paola, et al.
Publicado: (2021)

Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One
por: Meroni, Pier Luigi, et al.
Publicado: (2021)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
por: Adorni, Maria Pia, et al.
Publicado: (2017)

Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts
por: Raschi, Elena, et al.
Publicado: (2018)

Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis
por: Raschi, Elena, et al.
Publicado: (2020)

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response
por: Palmroth, Maaria, et al.
Publicado: (2021)

Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
por: Khalifa, Amr, et al.
Publicado: (2023)

Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion
por: Zanotti, Ilaria, et al.
Publicado: (2013)

Tofacitinib Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury by Blocking the JAK-STAT1/STAT3 Signaling Pathway
por: Yun, Yang, et al.
Publicado: (2021)

Author Correction: Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
por: Khalifa, Amr, et al.
Publicado: (2023)

A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC
por: Adorni, Maria Pia, et al.
Publicado: (2023)

Alcohol Pattern Consumption Differently Affects the Efficiency of Macrophage Reverse Cholesterol Transport in Vivo
por: Greco, Daniela, et al.
Publicado: (2018)

New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats
por: Durigutto, Paolo, et al.
Publicado: (2019)

Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations
por: Meroni, Pier Luigi, et al.
Publicado: (2014)

Drug-drug interactions in polypharmacy patients: The impact of renal impairment
por: Papotti, Bianca, et al.
Publicado: (2021)

Analysis of Serum Cholesterol Efflux Capacity in a Minipig Model of Nonischemic Heart Failure
por: Bigazzi, Federico, et al.
Publicado: (2017)

Tofacitinib Promotes Functional Recovery after Spinal Cord Injury by Regulating Microglial Polarization via JAK/STAT Signaling Pathway
por: Ma, Hongdao, et al.
Publicado: (2023)

HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study
por: Papotti, Bianca, et al.
Publicado: (2021)

Tofacitinib protects intestinal epithelial cells against oxygen-glucose deprivation/reoxygenation injury by inhibiting the JAK/STAT3 signaling pathway
por: Yang, Jing, et al.
Publicado: (2021)

The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice
por: Wang, Han, et al.
Publicado: (2019)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Tofacitinib reduces acute lung injury and improves survival in a rat model of sepsis by inhibiting the JAK-STAT/NF-κB pathway
por: Zhang, Xinxin, et al.
Publicado: (2023)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1oscj9aobtf98dds7id8ks322r